R. Peck

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

Lawrence B. Snyder, John J. Flanagan, Yimin Qian et al. · Cancer Research · 2021 · 105 citations

Breast Oncology, Estrogen Receptor, Pharmacotherapy +20

Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer

Lawrence B. Snyder, Taavi K. Neklesa, Xin Chen et al. · Cancer Research · 2021 · 69 citations

Androgen Receptor, Pharmacotherapy, Ubiquitin Proteomics +22

Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes

Linda T. Vahdat, E. Donnall Thomas, R. Li et al. · Journal of Clinical Oncology · 2007 · 32 citations

Metastatic Breast Cancer, Oncology, Health Sciences +14

A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer.

Edith A. Perez, Xavier Pivot, Eduard Vrdoljak et al. · Cancer Research · 2009 · 21 citations

Ixa-induced Pn, Neuropathic Pain, Pharmacotherapy +20

Apoptotic pathways of epothilone BMS 310705

Denise Uyar, Nagio Takigawa, Tarek Mekhail et al. · Gynecologic Oncology · 2003 · 19 citations

Medicine, Apoptosis, Autophagy +7